Foundation / Corporation
Alzheimer's Drug Discovery Foundation (ADDF)
11/08/19 5:00 PM ET Receipt
Grants to USA, Canada, and International nonprofits, universities, academic medical centers, and biotechnology companies for biomarkers research that will further the development of Alzheimer’s therapies. LOIs must be submitted before applying. New applicants are advised to allow 1-2 business days for registration in the online application portal.
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use that include but are not limited to:
1. Clearly demonstrate target engagement for novel therapeutics: The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers.
2. Detect signs of disease earlier and monitor progression. ADDF is seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. ADDF also seeks prognostic markers that can predict rates of cognitive decline.
3. More accurately diagnose and distinguish between dementia subtypes: Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.
Biomarker Targets - Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include, but are not limited to:
- Vascular injury or blood-brain barrier integrity
- Mitochondria & metabolic function
- Protein misfolding/proteostasis
- Oxidative stress
- White matter changes
- Other novel targets and pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process are encouraged.
All proposals should address the following:
- Potential for Commercial Translation
- Context of Use
- How the Proposed Biomarker Compares to Currently Available Biomarkers
For details on the above areas and on Expectations and Evaluation, see the URL for Full Text link below.
GrantWatch ID#: 181960
Average Award: $150,000 - $600,000 based on stage and scope of research; Larger amounts will be considered for PET ligand development for regulatory or clinical work.
Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered.
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
For program-related inquiries, please contact:
Meriel Owen, PhD, Scientific Program Officer
For application submission inquiries, please contact:
Grants and Mission-Related Investments Team
USA: Alabama; Alaska; Arizona; Arkansas; California; Colorado; Connecticut; Delaware; Florida; Georgia; Hawaii; Idaho; Illinois; Indiana; Iowa; Kansas; Kentucky; Louisiana; Maine; Maryland; Massachusetts; Michigan; Minnesota; Mississippi; Missouri; Montana; Nebraska; Nevada; New Hampshire; New Jersey; New Mexico; New York City; New York; North Carolina; North Dakota; Ohio; Oklahoma; Oregon; Pennsylvania; Rhode Island; South Carolina; South Dakota; Tennessee; Texas; Utah; Vermont; Virginia; Washington, DC; Washington; West Virginia; Wisconsin; Wyoming
USA Territories: American Samoa (USA) Guam (USA) Puerto Rico (USA) Virgin Islands (USA) Northern Mariana Islands (USA)
USA Compact Free Associations: The Federated States of Micronesia (USA) Marshall Islands (USA) Republic of Palau (USA)
Canada: Alberta British Columbia Manitoba New Brunswick Newfoundland and Labrador Northwest Territories Nova Scotia Nunavut Ontario Prince Edward Island Quebec Saskatchewan Yukon
International country outside of the USA, Israel and Canada.